MRD Response-adapted Allo-HSCT for Adverse-risk AML - Trial NCT06301425
Access comprehensive clinical trial information for NCT06301425 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University People's Hospital and is currently Not yet recruiting. The study focuses on Acute Myeloid Leukemia. Target enrollment is 178 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University People's Hospital
Timeline & Enrollment
N/A
May 01, 2024
May 01, 2028
Primary Outcome
Event-free survival (EFS)
Summary
This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD
 response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label,
 randomized, controlled trial.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06301425
Non-Device Trial